GLOSSARY · PHARMACY

503A compounding, custom medicine made for one patient.

503A compounding is a type of pharmacy compounding that lets a state-licensed pharmacy make a custom medication for one specific patient, based on that patient's prescription.

01

What it means

The name comes from section 503A of the federal Food, Drug, and Cosmetic Act. A 503A pharmacy is regulated mainly by its state board of pharmacy. Its compounded drugs are not FDA-approved, and it does not follow the manufacturing rules drug makers follow, because each product is made for a named patient with a prescription.

The law limits what a 503A pharmacy can make. It may not regularly compound drugs that are essentially copies of a commercially available drug. The exceptions include a drug on the FDA shortage list and a change the prescriber decides makes a significant difference for that patient. When a drug comes off the shortage list, compounders lose the ability to make routine copies of it, which is what happened to compounded semaglutide and tirzepatide.

02

Why it matters to a brand operator

Many telehealth programs in weight loss, hormones, hair loss, and peptides rely on compounded drugs, so the pharmacy's legal footing is a business risk. A program built on a compounded copy of a branded drug can lose its supply when the branded drug leaves the shortage list, and every patient then has to move to a different drug or dose form.

A brand should confirm that each compounding pharmacy is licensed in every state it ships to, that prescriptions are truly patient-specific, that patients are told the drug is compounded and not FDA-approved, and that marketing never implies FDA approval. The FDA has sent warning letters to telehealth companies over misleading claims about compounded drugs.

[  03  ]

How Tessic Health handles it

Tessic Health contracts the pharmacy network for each client's patients, passes medication through at wholesale with 0% markup, and ships temperature-sensitive medication through cold-chain fulfillment. Whether a patient receives a compounded or an FDA-approved drug stays a clinical decision for the prescriber.

See the published terms